Summary of Study ST003792

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002369. The data can be accessed directly via it's Project DOI: 10.21228/M8DR7V This work is supported by NIH grant, U2C- DK119886.

See: https://www.metabolomicsworkbench.org/about/howtocite.php

This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003792
Study TitleUntargeted lipidomics characterization of blood samples from patients with maple syrup urine disease (MSUD) in comparison to healthy controls
Study SummaryLipidomics analysis was performed on blood samples from MSUD patients and MSUD patients post-liver transplantation in comparison to healthy controls.
Institute
University of Colorado Denver
Last NameHaines
First NameJulie
Address12801 E 17th Ave, Room 1303, Aurora, Colorado, 80045, USA
Emailjulie.haines@cuanschutz.edu
Phone3037243339
Submit Date2025-03-10
Raw Data AvailableYes
Raw Data File Type(s)mzML, raw(Thermo)
Analysis Type DetailLC-MS
Release Date2025-06-05
Release Version1
Julie Haines Julie Haines
https://dx.doi.org/10.21228/M8DR7V
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR002369
Project DOI:doi: 10.21228/M8DR7V
Project Title:Advancing the Biochemical Understanding of Maple Syrup Urine Disease and the impact of liver transplantation: A Pilot Study
Project Summary:Maple syrup urine disease (MSUD) is a rare autosomal recessive metabolic disorder caused by impaired catabolism of branched-chain amino acids (BCAAs), leading to severe systemic dysregulation. The disease has an incidence of approximately 1 in 185,000 live births in the general U.S. population, with much higher prevalence in the Mennonite communities (up to 1 in 140 live births in the latter due to the c.1312T>A p.Tyr438Asn BCKDHA founder mutation). Using a multi-omics approach integrating metabolomics, lipidomics, and proteomics, we analyzed blood samples from three MSUD patients on a BCAA-restricted diet, two post-liver transplantation patients, and six healthy controls. Gene ontology analysis highlighted enriched pathways in MSUD, including glycolysis, oxidative phosphorylation, and purine metabolism, revealing systemic metabolic imbalances. Lipidomics indicated disruptions in sphingolipids and lysophosphatidylcholines, which impact cellular signaling and membrane integrity. Liver transplantation corrected some abnormalities, but several metabolites and proteins remained dysregulated. Proteomic analysis revealed significant alterations in redox homeostasis, energy metabolism, and cytoskeletal organization, with only partial recovery post-transplantation. Post-translational modifications, such as methylation and cysteine oxidation, suggested ongoing oxidative stress and immune activation in the LT group. Elevated levels of L-isoleucine, L-valine, and their ketoacids persisted post-transplant, correlating with impaired amino acid metabolism, lipid remodeling, and protein folding. These findings provide comprehensive insight into MSUD-associated metabolic dysfunctions and highlight potential therapeutic targets to improve patient outcomes.
Institute:University of Colorado Denver
Laboratory:Angelo D'Alessandro in collaboration with D. Holmes Morton
Last Name:Haines
First Name:Julie
Address:12801 E 17th Ave, Room 1303, Aurora, Colorado, 80045, USA
Email:julie.haines@cuanschutz.edu
Phone:3037243339

Subject:

Subject ID:SU003926
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Gender:Male and female

Factors:

Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Disease state
SA413021AG-88-1Healthy control
SA413022AG-88-2Healthy control
SA413023AG-88-3Healthy control
SA413024AG-88-4Healthy control
SA413025AG-88-5Healthy control
SA413026AG-88-6Healthy control
SA413029AG-88-7MSUD
SA413030AG-88-8MSUD
SA413031AG-88-9MSUD
SA413027AG-88-10MSUD with transplant
SA413028AG-88-11MSUD with transplant
SA413032AG-88-12Pool of MSUD with transplant
Showing results 1 to 12 of 12

Collection:

Collection ID:CO003919
Collection Summary:The study was conducted in accordance with the Declaration of Helsinki; specimens were collected at the Central Pennsylvania Clinic, Boston Children’s Hospital, and Lancaster General Hospitals under institutionally reviewed Protocol No. 2014-12 and upon signing of informed consent. Blood collections were carried out using standard equipment and clinical procedures. To study the metabolic changes occurring in patients with maple syrup urine disease, whole blood was collected from 3 patients having diagnosis of MSUD with a biallelic inactivating mutation of BCKDHA (c.1312T>A p.Tyr438Asn). Additional samples were collected from 6 healthy controls. Finally, samples were collected from two patients having a previous diagnosis of MSUD, but who had received liver transplantations to cure their condition. These two samples were combined 1:1, v:v, to generate a third replicate for statistical analysis.
Sample Type:Blood (whole)

Treatment:

Treatment ID:TR003935
Treatment Summary:No treatment was performed

Sample Preparation:

Sampleprep ID:SP003932
Sampleprep Summary:Blood aliquots were thawed on ice, then 10 uL of whole blood was treated with with 90 uL of cold methanol. Samples were vortexed 30 min at 4 degrees C then supernatants clarified by centrifugation (10 min, 10,000 g, 4 degrees C) and transferred to autosampler vials.
Processing Storage Conditions:4℃
Extract Storage:-80℃

Chromatography:

Chromatography ID:CH004725
Chromatography Summary:Negative C18
Instrument Name:Thermo Vanquish
Column Name:Phenomenex Kinetex C18 (30 x 2.1mm,1.7um)
Column Temperature:50
Flow Gradient:0-3 min 10-95% B at 0.3 mL/min, 3-4.2 min hold at 95% B at 0.3 mL/min, 4.2-4.3 min drop to 10% B at 0.45 mL/min, 4.3-4.9 min hold at 10%B while lowering flow rate to 0.4 mL/min, 4.9-5 min hold at 10%B while lowering flow rate to 0.3 mL/min.
Flow Rate:0.3 mL/min - 0.45 mL/min
Sample Injection:10 uL
Solvent A:75% water/25% acetonitrile; 5 mM ammonium acetate
Solvent B:90% isopropanol/10% acetonitrile; 5 mM ammonium acetate
Chromatography Type:Reversed phase
  
Chromatography ID:CH004726
Chromatography Summary:Positive C18
Instrument Name:Thermo Vanquish
Column Name:Phenomenex Kinetex C18 (30 x 2.1mm,1.7um)
Column Temperature:50
Flow Gradient:0-3 min 30-100% B at 0.3 mL/min, 3-4.2 min hold at 100% B at 0.3 mL/min, 4.2-4.3 min 100-30% B at 0.4 mL/min, 4.3-4.9 min hold at 30%B and 0.4 mL/min, 4.9-5 min hold at 30%B while lowering flow rate to 0.3 mL/min
Flow Rate:0.3 mL/min - 0.4 mL/min
Sample Injection:10 uL
Solvent A:75% water/25% acetonitrile; 5 mM ammonium acetate
Solvent B:90% isopropanol/10% acetonitrile; 5 mM ammonium acetate
Chromatography Type:Reversed phase

Analysis:

Analysis ID:AN006233
Analysis Type:MS
Chromatography ID:CH004725
Num Factors:4
Num Metabolites:207
Rt Units:Minutes
Units:peak area
  
Analysis ID:AN006234
Analysis Type:MS
Chromatography ID:CH004726
Num Factors:4
Num Metabolites:460
Rt Units:Minutes
Units:peak area
  logo